Results section (Page 11, line 346): There was no difference in NR2F1 expression between responder and non-responder to neoadjuvant endocrine therapy (Supplementary Fig. 9).
Kaplan-Meier curves of overall survival (OS), disease- specific survival (DSS), and disease-free survival (DFS) based on the high and low NR2F1 expression in triple-negative breast cancer of three large cohorts.